Objective:In spite of all efforts, prostate cancer is still the 2 nd highest cause of cancer-related deaths in men. For this reason new developments are needed in diagnosis, treatment and follow-up of prostate cancer. Neutrophil/lymphocyte (N/L) ratio is a cheap and effective parameter used for research into many solid tumors; but there are not enough studies on the reliability of this parameter in prostate cancer. In this study we researched the efficacy of N/L ratio in localized prostate cancer. Materials and Methods: Between March 9, 2012 and April 23, 2017, the data of 140 patients who underwent radical prostatectomy with localized prostate cancer were screened retrospectively. The patients' ages, preoperative prostate specific antigen (PSA) and N/L ratio, pathologic stage, pathologic Gleason score, tumor volume, lymph node involvement, surgical margin positivity and presence or absence of 3 rd month biochemical recurrence were noted. The correlations between N/L ratio with age, PSA, pathologic parameters, surgical margin positivity and biochemical recurrence were investigated. Results: The mean age of patients was 63.0±5.9 years, mean PSA value was 10.8±8.5 ng/mL and mean N/L ratio was 2.5±1.9. There was no correlation found between N/L ratio and PSA, pathologic stage, Gleason score, lymph node involvement, tumor volume, surgical margin positivity and biochemical recurrence (p>0.05). Conclusion: In our study investigating 140 patients with localized prostate cancer, we did not identify any correlation between N/L ratio and PSA, surgical stage and Gleason score, surgical margin positivity, and 3 rd month biochemical recurrence. When the literature is investigated, it appears that N/L ratio is effective for metastatic prostate cancer. To provide a more accurate judgment of the role of N/L ratio in localized prostate cancer, there is a need for new studies with broader patient series. Keywords: Inflammation, neutrophil-to-lymphocyte ratio, prostate cancer Amaç: Tüm uğraşılara rağmen prostat kanseri halen erkeklerde kanser nedenli ölümlerin 2. nedenidir. Bu sebeplerle prostat kanserinin tanı, tedavi ve izleminde yeni gelişmelere ihtiyaç duyulmaktadır. Nötrofil/ lenfosit (N/L) oranı birçok solid tümörde hakkında araştırma yapılan ucuz ve etkin bir parametredir, fakat prostat kanserinde bu parametrenin güvenilirliği konusunda yeterli sayıda çalışma bulunmamaktadır. Biz bu çalışmamızda lokalize prostat kanserinde N/L oranının etkinliğini araştırdık. Gereç ve Yöntem: 9 Mart 2012 ile 23 Nisan 2017 tarihleri arasında lokalize prostat kanseri tanısıyla radikal prostatektomi uygulanan 140 hastanın verileri retrospektif olarak tarandı. Hastaların yaş, preoperatif prostat spesifik antijen (PSA) ve N/L oranı, patolojik evre, patolojik Gleason skoru, tümör volümü, lenf nodu tutulumu, cerrahi sınır pozitifliği ve 3. ay biyokimyasal nüks bulunup bulunmadığı not edildi. N/L oranının yaş, PSA, patolojik parametreler, cerrahi sınır pozitifliği ve biyokimyasal nüks ile ilişkisi incelendi. Bulgular: Hastaların ortalama yaşı 63,0±...